Foghorn Therapeutics Inc. (FHTX) stock

FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/300% above fair value

$2.05−0.04 (-1.91%)

Close on Nov 12, 2026Market cap $121.74MP/E 29.3Yield –

Foghorn Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Foghorn Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Foghorn Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is FHTX.

Revenue growth357.3% · median -58.3%

Operating margin2.1% · median -189.4%

Net margin8.4% · median -169.8%

Advertisement
300 × 250

See a number that looks wrong?